New appointments at Cerenis Therapeutics

Cerenis Therapeutics (France/US), a privately held pharmaceutical company developing novel HDL therapies to treat cardiovascular and other metabolic diseases, has made the following appointments: Tom Brya joins as senior vice-president of business development, having previously served as vice-president and general manager for a biologic CMO start-up at Cardinal Health (now part of Catalent Pharma Services); Christopher Prue, who has 30 years' pharmaceutical industry experience, having held roles at AtheroGenics, Purdue Pharma, Incara Pharmaceuticals, Glaxo Wellcome and The Upjohn Company, becomes vice-president of regulatory affairs; and Dr Cynthia Sundell joins as vice-president of drug development; she formerly led discovery efforts at AtheroGenics.